Non-Alcoholic Fatty Liver Disease in Liver Transplant Recipients: Another Story of “Seed and Soil”

[1]  J. Botha,et al.  Immunosuppression in liver transplantation. , 2009, Current drug targets.

[2]  A. Diehl,et al.  De Novo nonalcoholic fatty liver disease after liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  Natalie J Torok,et al.  De novo nonalcoholic fatty liver disease after liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  A. Penfornis,et al.  Immunosuppressive drug-induced diabetes. , 2006, Diabetes & metabolism.

[5]  C. Day,et al.  Genes or environment to determine alcoholic liver disease and non‐alcoholic fatty liver disease , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[6]  R. Malthaner,et al.  Cyclosporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation: A Meta‐Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  T. Asselah,et al.  Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. , 2006, Gastroenterology.

[8]  K. Kowdley,et al.  Natural History of Nonalcoholic Steatohepatitis , 2006, Journal of clinical gastroenterology.

[9]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[10]  A. Burke,et al.  Non‐Alcoholic Fatty Liver Disease, Non‐Alcoholic Steatohepatitis and Orthotopic Liver Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[12]  L. Miller.  Cardiovascular Toxicities of Immunosuppressive Agents , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  R. Karim,et al.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.

[14]  G. Pacini,et al.  Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association , 2002, Hepatology.

[15]  P. Moulin,et al.  Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes , 2000, Diabetologia.

[16]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[17]  K. Tanikawa,et al.  Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. , 1997, Journal of hepatology.

[18]  G. Farrell,et al.  LIVER FAILURE AND LIVER DISEASE Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis , 2006 .

[19]  Yasuro Futagawa,et al.  An analysis of the OPTN/UNOS Liver Transplant Registry. , 2004, Clinical transplants.

[20]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.